Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Non-Current Liabilities (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $1.7 million for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Liabilities hit $1.7 million in Q4 2025 for Sutro Biopharma, roughly flat from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q4 2023 to a low of $119000.0 in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $1.1 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 91.16% in 2022 and later skyrocketed 1323.53% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $146000.0 in 2021, then fell by 18.49% to $119000.0 in 2022, then surged by 1323.53% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for STRO at $1.7 million in Q4 2025, $1.7 million in Q3 2025, and $1.7 million in Q2 2025.